Piper vs Care Bare Rx
A held rate at $146 against a rising one at $199, both nationwide.
Disclosure: Buy This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Piper
Editorial
$146/mo
One published figure per molecule, with no membership charge beside either: $135 for compounded semaglutide and $199 for compounded tirzepatide. Each buys a four-week dosage rather than a calendar month, so thirteen fills land in a year. Coverage is stated across 50 states and the rate is stated to hold at every dose.
Pick it for: Buyers budgeting past the first few months
Care Bare Rx
Partner
$199/mo
Semaglutide and tirzepatide are both $199 a month, injection only. There is no oral line and no price gap between the molecules, so the usual tirzepatide premium does not apply here. Fifty states. The catalog also runs to hair, NAD+ and sexual health.
Pick it for: Buyers who want tirzepatide without the usual premium
Our verdict
Piper states its figure is flat; Care Bare Rx's rises with the dose. The $53 opening gap is the narrowest it will ever be.
What actually separates them
Piper and Care Bare Rx state different things about published price. Everything else they publish, they publish the same way.
Care Bare Rx costs $53 more than Piper — 36% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,752 at Piper against $2,388 at Care Bare Rx — a difference of $636.
| Piper | Care Bare Rx | |
|---|---|---|
| Published price | $146/mo | $199/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.